396 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Whipplewood Advisors LLC

Whipplewood Advisors LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, HoldingsChannel reports. The fund acquired 396 shares of the medical research company’s stock, valued at approximately $103,000.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. AMF Tjanstepension AB lifted its holdings in shares of Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after purchasing an additional 17,387 shares in the last quarter. Swedbank AB lifted its holdings in shares of Amgen by 1.1% in the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after purchasing an additional 5,751 shares in the last quarter. Nicholas Hoffman & Company LLC. lifted its holdings in shares of Amgen by 23.3% in the third quarter. Nicholas Hoffman & Company LLC. now owns 1,033 shares of the medical research company’s stock valued at $333,000 after purchasing an additional 195 shares in the last quarter. Diversify Wealth Management LLC lifted its holdings in shares of Amgen by 26.5% in the third quarter. Diversify Wealth Management LLC now owns 4,647 shares of the medical research company’s stock valued at $1,463,000 after purchasing an additional 973 shares in the last quarter. Finally, Cornerstone Wealth Group LLC lifted its holdings in shares of Amgen by 1.0% in the third quarter. Cornerstone Wealth Group LLC now owns 12,944 shares of the medical research company’s stock valued at $4,171,000 after purchasing an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Piper Sandler upped their price target on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. UBS Group reissued a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price objective on shares of Amgen in a research report on Tuesday, November 12th. Leerink Partners cut their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Wolfe Research began coverage on shares of Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating for the company. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $314.09.

Amgen Price Performance

Amgen stock opened at $305.82 on Friday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a fifty day moving average of $279.97 and a 200-day moving average of $300.24. The firm has a market capitalization of $164.29 billion, a P/E ratio of 40.51, a PEG ratio of 2.63 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.11%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is presently 126.09%.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 over the last 90 days. Corporate insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.